Compounded Semaglutide vs Wegovy: What Is Actually Different

Brand Wegovy is FDA-approved, made to a fixed standard and sold in prefilled pens or tablets. Compounded semaglutide is not FDA-approved, which means the agency does not check its safety, effectiveness or quality before it is sold (FDA). Since the semaglutide shortage ended in February 2025, compounders can no longer make routine copies of Wegovy. Brand prices have also dropped: Novo Nordisk's own pharmacy now sells Wegovy pens from $199 to $349 a month and the pill from $149 (NovoCare Pharmacy).

What is the actual difference?

The medicine in Wegovy is semaglutide, made by Novo Nordisk under FDA approval, and it comes with the trial results behind it. In the main trial, adults lost about 15% of their weight over 68 weeks on Wegovy 2.4 mg (STEP 1, NEJM 2021).

Compounded semaglutide is mixed by a pharmacy from raw ingredient. It was never tested in those trials, and quality depends on the pharmacy. The FDA warns that some compounders have used salt forms, semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in the approved drug. The agency says it has no information on whether they act the same way and knows of no lawful basis for compounding with them (FDA).

Is compounded semaglutide still legal?

Much less of it is. The FDA declared the semaglutide injection shortage resolved on February 21, 2025. The grace period for state-licensed pharmacies has ended, and the one for larger outsourcing facilities ran until May 22, 2025. As of April 2026, semaglutide is not on the FDA's shortage list or the list of bulk ingredients outsourcing facilities may use (FDA compounding policy update).

A pharmacy can still compound semaglutide for one patient when a prescriber documents that the patient needs a meaningful change from the approved product. The FDA says it may treat routine mixes, such as semaglutide plus vitamin B12 given as a shot, as copies of the approved drug (FDA compounding policy update). In March 2026 the FDA sent warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1s (FDA press announcement). Our 2026 compounding rules guide tracks the broader picture.

How does dosing differ?

Wegovy comes in prefilled pens with fixed doses, or as a daily tablet. Compounded semaglutide usually comes as a vial you draw up with a syringe. A poison control case series described people taking 10 times their intended dose after confusing milliliters, units and milligrams, with days of vomiting and stomach pain. The authors noted vials lack the safety features of prefilled pens (Lambson 2023, JAPhA).

What does each cost?

Wegovy's self-pay prices through NovoCare Pharmacy:

• Wegovy pill: $149 a month for 1.5 mg, $199 for 4 mg, $299 for 9 mg and 25 mg.
• Wegovy pen: new patients pay $199 a month for the first two fills of the starting doses, through December 31, 2026, then $349 a month for doses up to 2.4 mg.
• With the savings offer: as little as $25 a month, up to $100 in monthly savings, with government insurance beneficiaries excluded (NovoCare Pharmacy).

Compounded prices vary by seller and change often. The FDA lists prices that seem too good to be true and claims that a compounded drug is "the same as" an approved drug among telehealth red flags (FDA). Our GLP-1 cost guide covers cash prices across options.

Comparison at a glance

Who each suits

Brand Wegovy suits almost everyone starting semaglutide now, especially women who want proven dosing, a pen or a pill, and a product backed by trial data. With self-pay prices down, the cost argument for compounding is weaker than it was in 2024.

Compounded semaglutide suits a narrow group: someone whose prescriber documents a specific medical need the approved product cannot meet. If you are offered it, check the pharmacy and product carefully; our guide to verifying a provider and pharmacy walks through how.

To get a weight plan matched to your goals and health history, take the HOD quiz.